We're seeing value health care (XLV) show a lot of relative strength against other sectors as the dollar has been pushing. (KRE) is often tied to growth when compared to it's bigger brother (XLF) and eventhough financials do tend to benefit from rising rates, this has been much more of a hard landing and the financial rotation many expect may not come to pass, instead look for XLV to continue soaking up 2022 when compared to other sectors.
biotechCAREChart PatternsdeflationdollarFundamental AnalysishealthinflationTrend Analysisvaccinesvaluestocks

Also on:

Disclaimer